Minerva Urology and Nephrology

Minerva Urology and Nephrology is the urology and nephrology journal of the Turin publisher Edizioni Minerva Medica, issued under its present title since 2021 as the successor of Minerva Urologica e Nefrologica, with a 2025 Journal Impact Factor of 5.1 at 17th of 134 titles in the field.《米涅瓦泌尿学与肾脏学》由都灵的（Edizioni Minerva Medica）出版，2021 年由（Minerva Urologica e Nefrologica）更名而来，2025 年期刊影响因子为 5.1，在泌尿学与肾脏学 134 种期刊中排名第 17。

Scope

• The journal treats urology and nephrology as one field, running from oncological and functional urology to renal medicine.本刊将泌尿学与肾脏学视为一个整体，覆盖肿瘤性与功能性泌尿疾病直至肾脏内科。
• Prostate cancer, kidney cancer and bladder cancer, including surgery, focal therapy and systemic treatment, form a large part of its output.前列腺癌、肾癌与膀胱癌（含手术、局灶治疗与全身治疗）构成本刊的重要部分。
• Benign prostatic obstruction, stone disease, urinary incontinence and reconstructive surgery sit alongside the oncology content.良性前列腺梗阻、结石病、尿失禁与重建手术与肿瘤内容并列。
• Minimally invasive and robot-assisted techniques, imaging and three-dimensional reconstruction are a recurring editorial focus.微创与机器人辅助技术、影像与三维重建是期刊反复关注的方向。
• Andrology, paediatric urology, transplantation, dialysis and other nephrological topics complete the coverage.男科、小儿泌尿、移植、透析及其他肾脏内科议题补足其覆盖范围。
• Original articles, reviews and editorials are published, with editorial comments and author replies attached to selected papers.刊物发表原创论文、综述与社论，并对部分论文配发编辑评论与作者回应。

History

• The journal carries the volume numbering of Minerva Urologica e Nefrologica, which it replaced in 2021 when volume 73 opened under the new title.本刊沿用（Minerva Urologica e Nefrologica）的卷号，2021 年以新刊名出版第 73 卷并取代旧刊。
• Both titles are issued from Turin by Edizioni Minerva Medica, an Italian medical publisher whose catalogue is built largely on clinical specialty journals.新旧两刊均由总部位于都灵的（Edizioni Minerva Medica）出版，该意大利医学出版社的产品线以临床专科期刊为主。
• The rename came with a redesigned journal and a restated programme, set out in the 2021 editorial MUN's new change of gear.更名同时伴随改版与办刊方案的重新表述，见于 2021 年社论（MUN's new change of gear）。
• Six issues appear each year in a single volume, published in English for an international readership.每年一卷共 6 期，以英文面向国际读者出版。
• The 2025 Journal Impact Factor is 5.1, after 4.2 in 2024 and 5.214 in 2022, ranking 17th of 134 in urology and nephrology at Q1.2025 年期刊影响因子为 5.1，2024 年为 4.2，2022 年为 5.214，在泌尿学与肾脏学类别位列 Q1，排名 17/134。
• Papers appear online with a DOI before they are collected into the bimonthly issue, and the title is indexed in SCIE, MEDLINE and Scopus.论文先以（DOI）在线发表，随后编入双月刊期次，本刊被（SCIE）、（MEDLINE）与（Scopus）收录。

Editors

• Francesco Porpiglia of the University of Turin, who works at the San Luigi Gonzaga Hospital in Orbassano and at the Candiolo Cancer Institute, is editor-in-chief.主编为都灵大学的（Francesco Porpiglia），他在奥尔巴萨诺的圣路易吉·贡扎加医院与坎迪奥洛癌症研究所任职。
• His clinical and research work centres on robot-assisted and minimally invasive urology, particularly prostate cancer and benign prostatic obstruction.他的临床与研究工作集中于机器人辅助与微创泌尿外科，尤其是前列腺癌与良性前列腺梗阻。
• Porpiglia writes the journal's lead editorials, among them MUN's new change of gear at the 2021 relaunch and a 2025 piece on how the field is shifting.（Francesco Porpiglia）撰写本刊的重点社论，包括 2021 年改版时的（MUN's new change of gear）以及 2025 年讨论学科变迁的一篇。
• Editorial comments and author replies are a standing feature, pairing commissioned commentary with the papers under discussion.编辑评论与作者回应是常设内容，把约稿评论与其讨论的论文配对刊出。
• Authors and reviewers come from urology and nephrology centres across Europe and beyond, and the journal publishes few but substantial issues a year.作者与审稿人来自欧洲及世界各地的泌尿与肾脏中心，期刊每年期数不多而篇幅充实。